GLP-1, GIP, and Glucagon: The Biology Behind the Best Weight Loss Peptides

The three most researched weight loss peptides in 2026 are defined by which hormone receptors they activate. Semaglutide activates GLP-1. Tirzepatide activates GLP-1 and GIP. Retatrutide activates GLP-1, GIP, and glucagon. To understand why each additional receptor improves outcomes, you need to understand what each of these three hormones does naturally and why activating them pharmacologically matters for metabolism.

GLP-1: The Original Incretin Hormone

GLP-1 (glucagon-like peptide-1) is produced by L-cells in the small intestine in response to food intake. When nutrients hit the gut, L-cells release GLP-1 into the bloodstream, where it acts on several targets. In the pancreas, GLP-1 stimulates beta cells to produce insulin in a glucose-dependent manner: insulin is released only when blood sugar is actually elevated, which prevents hypoglycemia. In the stomach, GLP-1 slows gastric emptying, meaning food moves more slowly from the stomach to the intestine, extending the feeling of fullness. In the brain, GLP-1 receptors in the hypothalamus and brainstem receive GLP-1 signals that suppress appetite.

The half-life of native GLP-1 is approximately 2 minutes, so its effects are short-lived. GLP-1 receptor agonists like semaglutide are engineered to produce the same receptor effects over much longer durations.

GIP: The Other Incretin

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, produced by K-cells in the duodenum and jejunum. Like GLP-1, it stimulates insulin secretion in a glucose-dependent way. For decades, GIP was thought to be primarily a redundant complement to GLP-1. More recent research has revealed that GIP receptor signaling in fat tissue plays a role in fat storage and release, and that the GIP pathway has a different receptor distribution than GLP-1, particularly in the central nervous system.

One of the key discoveries driving interest in GIP is that the combination of GLP-1 and GIP receptor agonism produces greater weight loss than GLP-1 agonism alone, which is not fully explained by simple additive effects. Research suggests GIP receptor activation may enhance the sensitivity of the GLP-1 pathway, creating synergistic rather than just additive effects. This is why tirzepatide produces more weight loss than semaglutide at comparable doses.

Glucagon: The Third Piece

Glucagon is produced by alpha cells in the pancreas and is classically known as the counter-regulatory hormone to insulin: while insulin lowers blood sugar by promoting glucose uptake, glucagon raises blood sugar by stimulating the liver to release stored glucose (glycogenolysis) and produce new glucose (gluconeogenesis). At first glance, adding glucagon receptor agonism to an insulin-enhancing compound seems contradictory.

The reason it works in metabolic research is that glucagon does more than regulate blood sugar. Glucagon also activates thermogenesis in brown adipose tissue, increasing the amount of energy the body burns at rest. It promotes fatty acid oxidation in the liver. These energy expenditure effects are independent of its glycemic effects and represent additional mechanisms for caloric expenditure beyond the appetite suppression provided by GLP-1 and GIP.

Why the Triple Combination Works

When all three pathways are activated simultaneously, as with retatrutide, the effects are complementary. GLP-1 reduces appetite and slows gastric emptying. GIP enhances the GLP-1 effect and plays a role in fat tissue signaling. Glucagon increases basal energy expenditure. The net effect is that the body is receiving less energy (through reduced appetite) and burning more energy (through thermogenesis), which creates a larger energy deficit than either mechanism alone.

The challenge with adding glucagon receptor agonism is managing the competing effects on blood sugar. Research shows that at the doses used in retatrutide trials, the insulin-enhancing effects of GLP-1 and GIP offset the glucose-raising effects of glucagon, resulting in neutral to positive glycemic outcomes overall.

How These Hormones Are Measured in Research

Researchers studying GLP-1 compounds typically measure several biomarkers to track the hormonal effects: fasting insulin, fasting glucose, HbA1c (a 3-month average of blood sugar), and GLP-1 levels (though these are difficult to measure accurately given the short half-life of native GLP-1). IGF-1 and growth hormone are less relevant in this class but may be measured if studying metabolic interactions broadly.

Werner Science provides research-grade compounds targeting all three of these receptor systems. Browse their catalog at wernerscience.com/?ref=bwmucbwp and use code SAVE10 for a discount.